Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Sumitomo Mitsui Trust Group Inc. cut its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 10.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,713,484 shares of the company's stock after selling 659,728 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 4.72% of 10x Genomics worth $82,046,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. KBC Group NV raised its holdings in shares of 10x Genomics by 38.8% during the third quarter. KBC Group NV now owns 3,225 shares of the company's stock worth $73,000 after acquiring an additional 902 shares during the period. First Horizon Advisors Inc. raised its stake in shares of 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after purchasing an additional 1,012 shares during the period. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock valued at $40,000 after purchasing an additional 1,025 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after buying an additional 1,265 shares during the period. Finally, Sound Income Strategies LLC grew its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have recently commented on TXG. Citigroup cut their price objective on shares of 10x Genomics from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday. UBS Group cut their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday. JPMorgan Chase & Co. decreased their price objective on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday. The Goldman Sachs Group lowered their target price on 10x Genomics from $16.00 to $14.00 and set a "sell" rating on the stock in a research report on Wednesday, October 30th. Finally, Morgan Stanley decreased their price target on 10x Genomics from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $20.71.

10x Genomics Stock Performance

Shares of TXG traded down $0.06 during trading hours on Thursday, reaching $11.94. The stock had a trading volume of 5,937,482 shares, compared to its average volume of 2,453,139. The company's 50-day moving average is $14.75 and its two-hundred day moving average is $17.43. The stock has a market capitalization of $1.45 billion, a PE ratio of -7.80 and a beta of 1.85. 10x Genomics, Inc. has a 12 month low of $10.80 and a 12 month high of $51.22.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. Equities analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.